These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Access to medicines and global health: will Canada lead or flounder? Orbinski J CMAJ; 2004 Jan; 170(2):224-6. PubMed ID: 14734437 [No Abstract] [Full Text] [Related]
4. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha. 't Hoen E Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298 [No Abstract] [Full Text] [Related]
6. Access to essential drugs, human rights and global justice. Shalev C Monash Bioeth Rev; 2004 Jan; 23(1):S56-74. PubMed ID: 15835024 [No Abstract] [Full Text] [Related]
7. Innovation and the WHO's essential medicines list: giving credit where credit is due. Wertheimer AI; Santella TM Res Social Adm Pharm; 2007 Mar; 3(1):137-44. PubMed ID: 17350562 [No Abstract] [Full Text] [Related]
8. Taking TRIPS to India--Novartis, patent law, and access to medicines. Mueller JM N Engl J Med; 2007 Feb; 356(6):541-3. PubMed ID: 17287473 [No Abstract] [Full Text] [Related]
9. Ensuring access to essential medicines: some economic considerations. Maskus KE Spec Law Dig Health Care Law; 2003 Jul; (291):9-25. PubMed ID: 15206162 [No Abstract] [Full Text] [Related]
10. The responsibility of research universities to promote access to essential medicines. 't Hoen EF Yale J Health Policy Law Ethics; 2003; 3(2):293-300. PubMed ID: 14577145 [No Abstract] [Full Text] [Related]
11. Commentary: will generic drug stores improve access to essential medicines for the poor in India? Kotwani A J Public Health Policy; 2010 Jul; 31(2):178-84. PubMed ID: 20535100 [No Abstract] [Full Text] [Related]
12. World pharmaceutical developments. Bale H World Hosp Health Serv; 2002; 38(2):1. PubMed ID: 12402745 [No Abstract] [Full Text] [Related]
13. [Access for all to quality drugs]. Videau JY Med Trop (Mars); 2002; 62(4):396-400. PubMed ID: 12534178 [TBL] [Abstract][Full Text] [Related]
14. Drugs are scarce as mix of programs aims to ease access. Brower V J Natl Cancer Inst; 2009 Oct; 101(19):1304-6. PubMed ID: 19755680 [No Abstract] [Full Text] [Related]
15. The GO License: only part of the solution. Batson A; Milstien JB Health Aff (Millwood); 2008; 27(1):140-2. PubMed ID: 18180489 [TBL] [Abstract][Full Text] [Related]
16. Reprivatizing pharmaceutical supplies in Africa. Turshen M J Public Health Policy; 2001; 22(2):198-225. PubMed ID: 11469153 [TBL] [Abstract][Full Text] [Related]
17. Access to essential medications for HIV/AIDS in South Africa. Andrews S S Afr Med J; 2001 May; 91(5):384-7. PubMed ID: 11455797 [No Abstract] [Full Text] [Related]
18. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health? Oliveira MA; Bermudez JA; Chaves GC; Velásquez G Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916 [TBL] [Abstract][Full Text] [Related]
19. Twenty-five years of essential medicines. Quick JD; Hogerzeil HV; Velasquez G; Rago L Bull World Health Organ; 2002; 80(11):913-4. PubMed ID: 12481216 [No Abstract] [Full Text] [Related]
20. An analysis of China's national essential medicines policy. Guan X; Liang H; Xue Y; Shi L J Public Health Policy; 2011 Aug; 32(3):305-19. PubMed ID: 21614030 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]